Drug intelligence / Profile preview

MP101

Development stage: Unknown
Lead developer: Microbiotix
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

MP101 is an investigational, intravenously administered bacteriophage cocktail developed by **MicrobiotiX** for acute *Pseudomonas aeruginosa* pneumonia. It contains two lytic phages, MXP1001 and MXP1002, selected to infect and lyse *P. aeruginosa*; the two-phage composition is intended to broaden coverage across clinically relevant bacterial strains. The phages were reported to lack lysogenic, antibiotic-resistance, and toxin-related genes. MP101 is being evaluated with standard antibiotic therapy in a randomized, double-blind, placebo-controlled Phase 1 study in adults with acute *P. aeruginosa* pneumonia. ([microbiotix.net](https://microbiotix.net/media/?bmode=view&idx=168494166))

Targets

P. aeruginosa (Pseudomonas aeruginosa)

Beyond the preview

Go deeper on MP101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MP101.

Explore the full profile